Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZYKXN)

Drug Name

PT320 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glucagon (GCG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PB-1023	DMZCI04	Type-2 diabetes	5A11	Phase 2	[3]
MK-8521	DMVNAYE	Type-2 diabetes	5A11	Phase 2	[3]
JNJ-64565111	DMVSUH1	Obesity	5B81	Phase 2	[3]
MEDI0382	DMSV60C	Type-2 diabetes	5A11	Phase 2	[3]
SAR425899	DM53IPE	Diabetic complication	5A2Y	Phase 1	[3]
ZP2929	DMRVDUM	Type-1 diabetes	5A10	Phase 1	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04269642) Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease. U.S.National Institutes of Health.
2	Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci. 2021 Mar 16;4(2):858-869.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)